DXRX — Diaceutics Income Statement
0.000.00%
- £137.09m
- £127.84m
- £32.16m
- 83
- 16
- 55
- 49
Annual income statement for Diaceutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.7 | 13.9 | 19.5 | 23.7 | 32.2 |
| Cost of Revenue | |||||
| Gross Profit | 9.46 | 12.2 | 16.7 | 19.7 | 28.3 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13.4 | 13.4 | 18.9 | 26.7 | 34.6 |
| Operating Profit | -0.658 | 0.55 | 0.575 | -3.02 | -2.46 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.682 | 0.462 | 0.564 | -2.44 | -1.91 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.263 | 0.561 | 0.724 | -1.75 | -1.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.263 | 0.561 | 0.724 | -1.75 | -1.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.263 | 0.561 | 0.724 | -1.75 | -1.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.007 | 0.007 | 0.008 | -0.021 | -0.019 |